Genenta Science S.p.A. (GNTA)
About Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $48.1M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $48.1M
- Shares outstanding
- 30.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 15, 2021
Genenta Science S.p.A. (GNTA) Stock Price
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Genenta Science S.p.A..
Write a review
News about Genenta Science S.p.A.
News & sentiment via Polygon.io
Genenta Science S.p.A.: frequently asked questions
Is Genenta Science S.p.A. an American company?
Genenta Science S.p.A. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Genenta Science S.p.A. publicly traded?
Yes — Genenta Science S.p.A. is a publicly traded company. Its stock trades under the ticker symbol GNTA on the NASDAQ.
What does Genenta Science S.p.A. do?
Genenta Science S.p.A. is an American Pharmaceuticals company in the Health & Beauty sector.
